RSS | Login | Register

CAPOZIDE 25/15

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare CAPOZIDE 25/15 to:

Generic Name for CAPOZIDE 25/15

Captopril 25mg, hydrochlorothiazide 15mg; scored tabs.

Legal Classification:

Pharmacological Class for CAPOZIDE 25/15

ACE inhibitor + diuretic.

Manufacturer of CAPOZIDE 25/15

Par Pharmaceutical, Inc.

Indications for CAPOZIDE 25/15

Hypertension.

Adult dose for CAPOZIDE 25/15

Take 1 hr before meals. As initial therapy: one 25/15 tab daily; adjust at 6 wk intervals. Previously titrated: use same doses as individual components. Usual max 150mg captopril, 50mg hydrochlorothiazide daily.

Children's dosing for CAPOZIDE 25/15

See literature.

Also:

CAPOZIDE 25/25

CAPOZIDE 50/15

CAPOZIDE 50/25

Contraindications for CAPOZIDE 25/15

Anuria. Sulfonamide allergy. History of ACEI-associated angioedema. Pregnancy (Cat.D in 2^nd and 3^rdtrimesters).

Warnings/Precautions for CAPOZIDE 25/15

Renal or hepatic dysfunction. Salt/volume depletion. CHF. Dialysis (esp. high-flux membrane). Aortic stenosis. Diabetes. Gout. Asthma. Postsympathectomy. Surgery. Monitor electrolytes. Monitor WBCs and renal function in renal and collagen vascular disease. Discontinue if neutropenia, agranulocytosis, angioedema or laryngeal edema occurs. Pregnancy (Cat.C in 1^sttrimester). Nursing mothers: not recommended.

Interactions for CAPOZIDE 25/15

Potentiated by antihypertensives. Potentiates tubocurarine. May antagonize sulfonylureas, oral anticoagulants, uricosurics. May be antagonized by NSAIDs, sympathomimetics. May increase digitalis, lithium, insulin, diazoxide toxicity. Hyperkalemia with potassium-sparing diuretics and supplements. Hypokalemia with ACTH, corticosteroids. Orthostatic hypotension may be increased by alcohol, CNS depressants. May interfere with parathyroid, urinary acetone tests.

Adverse Reactions for CAPOZIDE 25/15

Neutropenia, agranulocytosis, proteinuria, nephrotic syndrome, orthostatic hypotension, fluid or electrolyte imbalance, rash, GI upset, dysgeusia, hyperglycemia, hyperuricemia, dizziness, headache, cough, pruritus, angioedema, tachycardia, chest pain, jaundice, blurred vision.

How is CAPOZIDE 25/15 supplied?

Tabs—100

Related Disease:

Hypertension

Tekamlo approved for hypertension

August 27, 2010

The FDA has approved Tekamlo (aliskiren and amlodipine tablets, from Novartis), a single, combination therapy tablet for the treatment of hypertension, alone or with other antihypertensive agents.

Tribenzor approved for treatment of hypertension

July 26, 2010

Daiichi Sankyo announced that the FDA has approved Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide tablets), a fixed-dose combination therapy for the treatment of hypertension in patients who are not adequately controlled on any two of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers, and diuretics.

FDA warns of dangerous ingredients in Joyful Slim herb supplement

July 22, 2010

The FDA is warning consumers that Joyful Slim herb supplement, marketed as a natural herb for weight loss, contains undeclared desmethyl sibutramine, an FDA-approved drug used as an appetite suppressant for weight loss.

FDA conducts safety review of cancer risk with angiotensin receptor blockers (ARBs)

July 15, 2010

A recently published meta-analysis combining cancer-related findings from several clinical trials is suggesting that angiotensin receptor blockers (ARBs) may be associated with a small increased risk of cancer.

FDA reviews cardiovascular mortality risk associated with Benicar

June 11, 2010

The FDA is evaluating data from two clinical trials in which patients with type 2 diabetes taking Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) had a higher rate of death from a cardiovascular cause compared to patients taking a placebo.